Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer
Eur Respir J
.
2022 Oct 27;60(4):2201289.
doi: 10.1183/13993003.01289-2022.
Print 2022 Oct.
Authors
Miriam Barrecheguren
1
,
Marc Miravitlles
2
Affiliations
1
Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain miriam.barrecheguren@vallhebron.cat.
2
Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.
PMID:
36302522
DOI:
10.1183/13993003.01289-2022
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Neoplasms* / complications
Registries
alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency* / complications
Substances
alpha 1-Antitrypsin